NCNA NuCana plc Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

NCNA [NASD]

NuCana plc

Healthcare | Biotechnology | United Kingdom

statements

Index	-	P/E	-	EPS (ttm)	-0.78	Insider Own	0.65%	Shs Outstand	31.88M	Perf Week	-5.94%
Market Cap	169.30M	Forward P/E	-	EPS next Y	-0.94	Insider Trans	0.00%	Shs Float	16.31M	Perf Month	-15.19%
Income	-25.00M	PEG	-	EPS next Q	-0.22	Inst Own	50.40%	Short Float	15.27%	Perf Quarter	3.36%
Sales	-	P/S	-	EPS this Y	-53.50%	Inst Trans	-0.56%	Short Ratio	36.85	Perf Half Y	-12.54%
Book/sh	2.48	P/B	2.11	EPS next Y	-13.00%	ROA	-22.50%	Target Price	-	Perf Year	-46.58%
Cash/sh	2.00	P/C	2.61	EPS next 5Y	-	ROE	-24.40%	52W Range	3.81 - 10.94	Perf YTD	-14.26%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-52.19%	Beta	-
Dividend %	-	Quick Ratio	10.50	Sales past 5Y	-	Gross Margin	-	52W Low	37.27%	ATR	0.33
Employees	31	Current Ratio	10.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	35.11	Volatility	4.27% 5.76%
Optionable	No	Debt/Eq	0.01	EPS Q/Q	-130.20%	Profit Margin	-	Rel Volume	0.58	Prev Close	5.39
Shortable	Yes	LT Debt/Eq	0.01	Earnings	-	Payout	-	Avg Volume	67.62K	Price	5.23
Recom	1.50	SMA20	-9.72%	SMA50	-10.38%	SMA200	-14.00%	Volume	38,927	Change	-2.92%

Aug-19-19

Initiated

H.C. Wainwright

Buy

$20

Oct-19-18

Initiated

Piper Jaffray

Overweight

Oct-23-17

Initiated

William Blair

Outperform

Oct-23-17

Initiated

Jefferies

Buy

$25

Oct-23-17

Initiated

Citigroup

Buy

$23

Jul-02-20 12:25PM	Blueprint Medicines Files NDA to FDA for Pralsetinib in MTC Zacks
Jun-29-20 12:49PM	Axsome's AXS-05 Gets Breakthrough Therapy Tag for AD Agitation Zacks
Jun-16-20 10:47AM	ACADIA Files sNDA for Nuplazid in Dementia-Related Psychosis Zacks
Jun-10-20 01:04PM	Immunic Gets FDA Allowance for Phase II Coronavirus Study Zacks
Jun-02-20 08:59AM	Why NuCana (NCNA) Stock Might be a Great Pick Zacks
Jun-01-20 12:20PM	Will NuCana Continue to Surge Higher? Zacks
May-28-20 10:54AM	Top Ranked Momentum Stocks to Buy for May 28th Zacks
May-27-20 09:34AM	5 Health Care Stocks to Bet on as Coronavirus Woes Linger Zacks +5.91%
07:00AM	NuCana to Present at the 2020 Jefferies Virtual Healthcare Conference GlobeNewswire
May-24-20 07:00AM	3 Strong Buy Healthcare Stocks That Could Double in the Next Year TipRanks
May-19-20 04:01PM	NuCana Reports First Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
May-18-20 07:00AM	NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic GlobeNewswire +6.52%
May-15-20 07:00AM	NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020 GlobeNewswire
May-05-20 04:01PM	NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121) GlobeNewswire
Apr-02-20 04:01PM	NuCana Provides Update on Impact of COVID-19 on Clinical Studies GlobeNewswire -9.65%
Mar-18-20 08:25AM	NuCana (NASDAQ:NCNA) Is In A Good Position To Deliver On Growth Plans Simply Wall St. -23.85%
Mar-11-20 08:03AM	The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment Benzinga -6.21%
Mar-10-20 04:02PM	NuCana Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update GlobeNewswire
04:01PM	NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer GlobeNewswire
Mar-04-20 07:00AM	NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer GlobeNewswire +15.29%
Feb-29-20 07:00AM	Harvard Sold Facebook, Palo Alto Stock. Heres What It Bought. Barrons.com
Feb-25-20 09:46AM	NuCana (NCNA) to Report Q4 Earnings: What's in the Cards? Zacks -7.22%
07:00AM	NuCana to Present at the Cowen and Company 40th Annual Health Care Conference GlobeNewswire
Jan-27-20 07:00AM	NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer GlobeNewswire +7.63%
Jan-03-20 10:54AM	Innate Pharma's Filing for Leukemia Drug Accepted in Europe Zacks
Dec-20-19 05:44PM	NuCana plc (NCNA): Are Hedge Funds Right About This Stock? Insider Monkey -6.44%
Dec-11-19 07:04AM	New Strong Buy Stocks for December 11th Zacks +7.94%
Nov-27-19 03:32AM	Sorrento Turns Down Two All-Cash Takeover Bids, Stock Jumps Zacks
Nov-26-19 07:00AM	NuCana to Participate in the Piper Jaffray 31st Annual Healthcare Conference GlobeNewswire
Nov-22-19 10:48AM	3 Strong Buy Stocks Set for Triple Digit Gains TipRanks +6.13%
Nov-20-19 09:50AM	Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH Zacks
Nov-14-19 07:00AM	NuCana to Present at the Jefferies 2019 London Healthcare Conference GlobeNewswire
Nov-13-19 04:01PM	NuCana Reports Third Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Oct-29-19 07:00AM	NuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire -5.20%
Oct-25-19 07:00AM	NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer GlobeNewswire
Oct-17-19 11:24AM	Lilly's Pancreatic Cancer Candidate Fails in Phase III Study Zacks +5.72%
Oct-16-19 12:15PM	Novavax Begins Phase III Study on Influenza Vaccine Candidate Zacks
Sep-20-19 11:12AM	What Percentage Of NuCana plc (NASDAQ:NCNA) Shares Do Insiders Own? Simply Wall St.
Sep-17-19 10:44AM	Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review Zacks -9.24%
Sep-16-19 08:48AM	Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study Zacks
Sep-10-19 06:00PM	FDA Grants Orphan Drug Status to Acceleron's PAH Candidate Zacks
Sep-06-19 10:06AM	NuCana plc (NCNA) Shares March Higher, Can It Continue? Zacks
Sep-03-19 11:00AM	Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why Zacks
Sep-02-19 09:17AM	Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease Zacks
Aug-29-19 08:00AM	NuCana to Present at the Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire +7.38%
Aug-27-19 08:00AM	NuCana to Participate in Citis 14th Annual Biotech Conference GlobeNewswire
Aug-21-19 04:01PM	NuCana Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
11:08AM	NuCana Stops Patient Enrollment in Pancreatic Cancer Study Zacks
Aug-20-19 11:00AM	NuCana stock falls 21% after company suspends patient enrollment in pancreatic cancer trial MarketWatch +9.29%
08:00AM	Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis GlobeNewswire
Aug-18-19 06:25PM	Analysts Recommend These 2 Falling Knives GuruFocus.com
Jul-18-19 11:18AM	NuCana Initiates Dosing in Phase I Study for Solid Tumors Zacks
Jul-17-19 07:00AM	NuCana Announces First Patients Dosed in Phase I Study of NUC-7738 GlobeNewswire
Jun-13-19 10:26AM	NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag Zacks
07:44AM	The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes Benzinga
Jun-12-19 07:24PM	NuCana Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin® for the Treatment of Biliary Tract Cancer GlobeNewswire
May-30-19 04:01PM	NuCana to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-14-19 04:01PM	NuCana Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Apr-02-19 08:00AM	NuCana to Participate in the William Blair 3rd Late-Stage Therapeutics Conference GlobeNewswire
Mar-30-19 10:27AM	Introducing NuCana (NASDAQ:NCNA), The Stock That Dropped 10% In The Last Year Simply Wall St.
Mar-18-19 06:28AM	Will NuCana Continue to Surge Higher? Zacks
Mar-07-19 04:01PM	NuCana Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-05-19 08:00AM	NuCana to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-27-19 04:45PM	NuCana to Present at the American Association for Cancer Research (AACR) Annual Meeting 2019 GlobeNewswire
Jan-25-19 08:32AM	NuCana's stock soars after withdrawing ADS offering, which triggered a big selloff MarketWatch +7.36%
08:15AM	NuCana plc Announces Withdrawal of Public Offering of ADSs GlobeNewswire
Jan-23-19 04:01PM	NuCana plc Announces Proposed Public Offering of ADSs GlobeNewswire
Jan-07-19 10:06AM	Amarin Down on Lower '19 View, Posts Preliminary '18 Results Zacks
Nov-28-18 04:01PM	NuCana to Participate in Citi's 2018 Global Healthcare Conference GlobeNewswire
Nov-27-18 04:01PM	NuCana Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Nov-20-18 07:00AM	NuCana to Participate in the 2018 Evercore ISI HealthCONx Conference GlobeNewswire
Nov-07-18 07:00AM	NuCana to Participate in the Jefferies 2018 London Healthcare Conference GlobeNewswire -8.26%
Nov-01-18 07:00AM	NuCana Announces First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer GlobeNewswire
Oct-24-18 05:30AM	NuCana Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-22-18 07:00AM	NuCana Presents Data from Phase I Study of NUC-3373 at ESMO 2018 GlobeNewswire -10.84%
Oct-21-18 06:54AM	NuCana Reports Additional Promising Clinical Data on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer at ESMO 2018 GlobeNewswire
Oct-09-18 01:15PM	NuCana to Present New Data from its ProTide Portfolio at the European Society for Medical Oncology (ESMO) 2018 Congress GlobeNewswire
Aug-29-18 04:01PM	NuCana to Participate in Citis 13th Annual Biotech Conference GlobeNewswire -5.46%
Aug-28-18 04:01PM	NuCana Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Jun-01-18 11:08AM	Better Know Biotech: 2 Stocks You've Got to Know About Motley Fool
May-25-18 04:01PM	NuCana to Participate in the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-23-18 04:02PM	NuCana Reports First Quarter 2018 Financial Results GlobeNewswire
May-21-18 07:01AM	NuCana Announces Appointment of Cyrille Leperlier to its Board of Directors GlobeNewswire +11.94%
07:00AM	NuCana Announces Appointment of Cyrille Leperlier to its Board of Directors GlobeNewswire
May-17-18 07:00AM	NuCana CEO Hugh Griffith Honored with the Outstanding Achievement Award from Life Sciences Scotland GlobeNewswire
Apr-09-18 07:01AM	NuCana plc Announces Appointment of Adam George to its Board of Directors GlobeNewswire
07:00AM	NuCana plc Announces Appointment of Adam George to its Board of Directors GlobeNewswire
Mar-21-18 04:09PM	NuCana Reports Financial Results for the Year Ended December 31, 2017 GlobeNewswire
Mar-02-18 08:01AM	NuCana plc to Participate in the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
08:00AM	NuCana plc to Participate in the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Jan-23-18 07:00AM	Wired News NuCana Announced Positive Results from Clinical Data on Acelarin® as Front-Line Treatment of Advanced Biliary Tract Cancer at ASCO GI 2018 ACCESSWIRE
Jan-22-18 09:59AM	Heres Whats Moving NuCana plc (NASDAQ:NCNA) and PHARMA MAR (OTCMKTS:PHMMF) Market Exclusive +6.29%
Jan-19-18 12:02PM	NuCana Announces Promising Clinical Data at ASCO GI on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer GlobeNewswire +41.55%
Nov-20-17 08:02AM	NuCana plc to Participate in the Evercore ISI Biopharma Catalyst / Deep Dive Conference GlobeNewswire
Nov-15-17 08:01AM	NuCana Announces First Patients Enrolled in Phase 2 Study of Acelarin in Platinum-Resistant Ovarian Cancer GlobeNewswire
Nov-02-17 08:00AM	NuCana plc to Present at the Jefferies 2017 London Healthcare Conference GlobeNewswire -12.11%
Oct-23-17 02:16PM	Analysts See Potential In The NuCana Pipeline Benzinga
Oct-02-17 02:28PM	NuCana plc Announces Closing of Initial Public Offering of ADSs and Exercise of Underwriters' Option to Purchase Additional ADSs GlobeNewswire
01:40PM	NuCana plc Announces Closing of Initial Public Offering of ADSs and Exercise of Underwriters Option to Purchase Additional ADSs GlobeNewswire
Oct-01-17 09:43AM	IPO News This Week: Data Center Firm Switch Tops a Short List 24/7 Wall St.

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience